ArticleCureus2025
Frequency of Celiac Disease in Irritable Bowel Syndrome: Insights From a Tertiary Care Hospital.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMany published studies have shown that the prevalence of celiac disease (CD) is higher in individuals with irritable bowel syndrome (IBS); however, the current available evidence is controversial. Moreover, controversy exists regarding the routine screening of CD in IBS patients, as the available results show conflicting evidence. Objective: This study aimed to determine the prevalence of CD in individuals with IBS presenting at a tertiary care hospital. METHODOLOGY: This one-year cross-sectional study was performed at District Headquarters (DHQ) Teaching Hospital, Gujranwala, Pakistan, between January 2019 and January 2020. A total of 260 persons, who fulfilled the inclusion and exclusion criteria, were selected through a non-probability consecutive sampling technique. Patients having positive anti-tissue transglutaminase (anti-TTG) IgA and IgG antibodies were diagnosed as having probable celiac disease (PCD). Data were collected and compiled using IBM SPSS Statistics for Windows, Version 23.0 (IBM Corp., Armonk, New York, United States). Post-stratification, the chi-squared test was applied, taking p≤0.05 as significant.
resultsThe mean age of the patients was 49.4±18.5 years. Gender distribution showed that 168 (64.6%) were males, while 92 (35.4%) were females. Among 260 patients, 39 (15%) were diagnosed with CD. Duration of IBS is associated with increased prevalence of CD, and this association is statistically significant (p<0.001). Conclusion: Patients with IBS, irrespective of age and gender, are more susceptible to develop CD compared to the general population. Based on these findings, we recommend routine screening for CD with serologic markers in all IBS patients to identify individuals with latent or potential CD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.